High-dose aflibercept maintains visual acuity in wet AMD

DENVER — High-dose aflibercept maintained visual acuity in patients with neovascular age-related macular degeneration at 48 months, according to a study presented at the Association for Research in Vision and Ophthalmology meeting.
Nicole K. Scripsema, MD, told Healio/OSN that she and colleagues wanted to take a closer look at their practice protocol for how patients respond to AMD treatment.
“For patients with [AMD], we’re very concerned about cost efficiency and cost of health care,” she said. “Everyone who comes in is started on Avastin (bevacizumab, Genentech).

DENVER — High-dose aflibercept maintained visual acuity in patients with neovascular age-related macular degeneration at 48 months, according to a study presented at the Association for Research in Vision and Ophthalmology meeting.
Nicole K. Scripsema, MD, told Healio/OSN that she and colleagues wanted to take a closer look at their practice protocol for how patients respond to AMD treatment.
“For patients with [AMD], we’re very concerned about cost efficiency and cost of health care,” she said. “Everyone who comes in is started on Avastin (bevacizumab, Genentech).